Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
LDP’s Hashimoto Regrets Election Defeat amid Off-Year Debate
Liberal Democratic Party member Gaku Hashimoto on October 29 expressed his apology over the loss of his seat in the recent Lower House election, regretting his absence in upcoming discussions on “off-year” drug price revisions that would culminate towards year’s…
To read the full story
Related Article
- With 1/4 of Pharma Backers Losing Seats, It’s Time for Industry to Revamp Lobbying Activities
November 11, 2024
- Ruling Bloc’s Loss of Lower House Majority Might Sway Off-Year Revision Debates
October 29, 2024
- LDP Loses Big in Snap Election, Many Health-Savvy Members Ousted
October 28, 2024
- LDP’s Hashimoto Makes Rare Speech on Drug Prices amid Close Race in Okayama
October 22, 2024
- Multiple Candidates Tout Drug Policies as Snap Poll Campaigning Starts
October 16, 2024
- Japan Political Parties Push Varied Pharma Policies as Election Campaign Kicks Off
October 15, 2024
- Pharma Industry Prepares List of 68 Lawmakers to Support in Likely Snap Poll
September 12, 2024
REGULATORY
- Takeda’s Miyabashira Urges National Strategy Act to Revive Japan as Innovation Powerhouse
January 22, 2026
- LDP Pledges to Position Pharma as Core Industry in Campaign Platform
January 22, 2026
- Many Pharma-Savvy Lawmakers on LDP’s Candidate Roster for Lower House Poll
January 22, 2026
- Japan Health Minister Says Early Call on FY2027 Off-Year Revision Improves Predictability
January 22, 2026
- Japan Grants Sakigake Tag to Nanoscope’s MOGENRY
January 22, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…